{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:41:54Z","timestamp":1783698114733,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"crossref","award":["JP21K16000"],"award-info":[{"award-number":["JP21K16000"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"crossref","award":["JP21K08006"],"award-info":[{"award-number":["JP21K08006"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["23fk0210083s0403"],"award-info":[{"award-number":["23fk0210083s0403"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hepatitis B virus (HBV) RNA is an important serum biomarker of hepatic covalently closed circular DNA (cccDNA) transcriptional activity; however, its clinical characteristics remain unclear. This study evaluated the clinical utility of HBV RNA levels in patients with chronic hepatitis B (CHB).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We studied 87 CHB patients with serum HBV DNA levels\u2009\u2265\u20095.0 log IU\/mL who initiated entecavir (ETV) treatment between 2000 and 2018. Serum HBV RNA levels were measured at three-time points: before ETV treatment, at 12\u00a0weeks, and at 48\u00a0weeks after starting ETV treatment. Clinical markers associated with the antiviral effects of ETV treatment were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Serum HBV RNA levels decreased in both HBeAg-positive and -negative patients during the observation period. In HBeAg-positive patients, multivariable analysis showed that lower HBV RNA levels at 48\u00a0weeks of ETV treatment were independently associated with HBeAg seroconversion. Additionally, lower baseline HBV RNA levels significantly predicted virologic response in those patients. In contrast, among HBeAg-negative patients, lower HBV core-related antigen (HBcrAg) levels and the FIB-4 index were independently associated with virologic response. In HBeAg-positive patients, those with higher baseline HBV RNA levels showed a more significant reduction in hepatitis B surface antigen levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Serum HBV RNA levels predicted HBeAg seroconversion and early HBV DNA reduction in HBeAg-positive patients, while HBcrAg was significantly associated with virologic response in HBeAg-negative patients. These findings highlight the different predictive roles of HBV RNA and HBcrAg based on HBeAg status, which may provide individualized treatment strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00535-025-02211-5","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:56:00Z","timestamp":1737536160000},"page":"469-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B"],"prefix":"10.1007","volume":"60","author":[{"given":"Masanari","family":"Kosaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4960","authenticated-orcid":false,"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clair Nelson","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Kashiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Mokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2211_CR1","unstructured":"World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240027077 Accessed on 13 May 2024"},{"issue":"9","key":"2211_CR2","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1478-3231.2012.02805.x","volume":"32","author":"UH Iloeje","year":"2012","unstructured":"Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int. 2012;32(9):1333\u201341. https:\/\/doi.org\/10.1111\/j.1478-3231.2012.02805.x. (Epub 2012 Apr 17 PMID: 22510145).","journal-title":"Liver Int"},{"key":"2211_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/scbi.2000.0321","volume":"10","author":"C Brechot","year":"2000","unstructured":"Brechot C, Gozuacik D, Murakami Y, et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol. 2000;10:211\u201331.","journal-title":"Semin Cancer Biol"},{"key":"2211_CR4","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/gut.2004.054452","volume":"54","author":"Y Murakami","year":"2005","unstructured":"Murakami Y, Saigo K, Takashima H, et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut. 2005;54:1162\u20138.","journal-title":"Gut"},{"key":"2211_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1101\/gad.1.8.773","volume":"1","author":"T Nagaya","year":"1987","unstructured":"Nagaya T, Nakamura T, Tokino T, et al. The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev. 1987;1:773\u201382.","journal-title":"Genes Dev"},{"key":"2211_CR6","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1128\/jvi.61.6.1808-1813.1987","volume":"61","author":"K Yaginuma","year":"1987","unstructured":"Yaginuma K, Kobayashi H, Kobayashi M, et al. Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children. J Virol. 1987;61:1808\u201313.","journal-title":"J Virol"},{"issue":"Suppl 1","key":"2211_CR7","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/S0168-8278(02)00431-2","volume":"38","author":"HS Conjeevaram","year":"2003","unstructured":"Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol. 2003;38(Suppl 1):S90-103.","journal-title":"J Hepatol"},{"key":"2211_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1872-034X.2009.00633.x","volume":"40","author":"H Kumada","year":"2010","unstructured":"Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40:1\u20137.","journal-title":"Hepatol Res"},{"key":"2211_CR9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/hep.21189","volume":"43","author":"YS Lee","year":"2006","unstructured":"Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385\u201391.","journal-title":"Hepatology"},{"key":"2211_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/oxfordjournals.bmb.a072402","volume":"46","author":"JC Pugh","year":"1990","unstructured":"Pugh JC, Bassendine MF. Molecular biology of hepadnavirus replication. Br Med Bull. 1990;46:329\u201353.","journal-title":"Br Med Bull"},{"key":"2211_CR11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.21581","volume":"45","author":"T Hatakeyama","year":"2007","unstructured":"Hatakeyama T, Noguchi C, Hiraga N, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology. 2007;45:1179\u201386.","journal-title":"Hepatology"},{"key":"2211_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3851\/IMP1508","volume":"15","author":"YW Huang","year":"2010","unstructured":"Huang YW, Chayama K, Tsuge M, et al. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antivir Ther. 2010;15:177\u201384.","journal-title":"Antivir Ther"},{"key":"2211_CR13","first-page":"2005","volume":"7","author":"Q Su","year":"2001","unstructured":"Su Q, Wang SF, Chang TE, et al. Circulating hepatitis B virus nucleic acids in chronic infection\u202f: representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res. 2001;7:2005\u201315.","journal-title":"Clin Cancer Res"},{"key":"2211_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jmv.10464","volume":"71","author":"W Zhang","year":"2003","unstructured":"Zhang W, Hacker HJ, Tokus M, et al. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. J Med Virol. 2003;71:24\u201330.","journal-title":"J Med Virol"},{"key":"2211_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","volume":"48","author":"M Tsuge","year":"2013","unstructured":"Tsuge M, Murakami E, Imamura M, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol. 2013;48:1188\u2013204.","journal-title":"J Gastroenterol"},{"key":"2211_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","volume":"66","author":"K Giersch","year":"2017","unstructured":"Giersch K, Allweiss L, Volz T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66:460\u20132.","journal-title":"J Hepatol"},{"key":"2211_CR17","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/hep.30325","volume":"69","author":"S Liu","year":"2019","unstructured":"Liu S, Zhou B, Valdes JD, et al. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology. 2019;69:1816\u201327.","journal-title":"Hepatology"},{"key":"2211_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcv.2017.12.016","volume":"99\u2013100","author":"H Huang","year":"2018","unstructured":"Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J Clin Virol. 2018;99\u2013100:71\u20138.","journal-title":"J Clin Virol"},{"key":"2211_CR19","unstructured":"Nihon Arukoru Igakkai\/Japenese Medical Society of Alcohol Studies. Guidelines for conflict of interest in clinical research Nihon Arukoru Yakubutsu Igakkai Zasshi Jpn. J Alcohol Stud Drug Depend. 2013; 48:339\u2013357 (In Japanese)."},{"key":"2211_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/hep4.1520","volume":"4","author":"B Maasoumy","year":"2020","unstructured":"Maasoumy B, Geretti AM, Frontzek A, et al. HBV-RNA Co-amplification may influence HBV DNA viral load determination. Hepatol Commun. 2020;4:983\u201397.","journal-title":"Hepatol Commun"},{"key":"2211_CR21","doi-asserted-by":"publisher","first-page":"e0214921","DOI":"10.1128\/spectrum.02149-21","volume":"10","author":"MF Cortese","year":"2022","unstructured":"Cortese MF, Riveiro-Barciela M, Tabernero D, et al. Standardized hepatitis B virus RNA quantification in untreated and treated chronic patients: a promising marker of infection follow-up. Microbiol Spectr. 2022;10:e0214921.","journal-title":"Microbiol Spectr"},{"key":"2211_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"2211_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2211_CR24","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.2147\/IDR.S252994","volume":"13","author":"X Ji","year":"2020","unstructured":"Ji X, Xia M, Zhou B, Liu S, et al. Serum hepatitis B virus RNA levels predict HBeAg seroconversion and virological response in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analog. Infect Drug Resist. 2020;13:1881\u20138.","journal-title":"Infect Drug Resist"},{"issue":"6","key":"2211_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3748\/wjg.v25.i6.719","volume":"25","author":"H Luo","year":"2019","unstructured":"Luo H, Zhang XX, Cao LH, et al. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients. World J Gastroenterol. 2019;25(6):719\u201328.","journal-title":"World J Gastroenterol"},{"key":"2211_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"2211_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int. 2017;11:317\u201370.","journal-title":"Hepatol Int"},{"key":"2211_CR28","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"2211_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/hepr.13504","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the management of hepatitis B virus infection: 2019 update. Hepatol Res. 2020;50:892\u2013923.","journal-title":"Hepatol Res"},{"key":"2211_CR30","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","volume":"126","author":"B Werle-Lapostolle","year":"2004","unstructured":"Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750\u20138.","journal-title":"Gastroenterology"},{"key":"2211_CR31","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1128\/AAC.42.12.3130","volume":"42","author":"AJ Nicoll","year":"1998","unstructured":"Nicoll AJ, Colledge DL, Toole JJ, et al. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother. 1998;42:3130\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2211_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1128\/AAC.46.2.425-433.2002","volume":"46","author":"J Delmas","year":"2002","unstructured":"Delmas J, Schorr O, Jamard C, et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother. 2002;46(2):425\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"2211_CR33","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Trepo","year":"2014","unstructured":"Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053\u201363.","journal-title":"Lancet"},{"key":"2211_CR34","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"L Tang","year":"2018","unstructured":"Tang L, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319:1802\u201313.","journal-title":"JAMA"},{"key":"2211_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa013","author":"M Farag","year":"2020","unstructured":"Farag M, Campenhout M, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to PEGylated interferon alfa in HBeAg negative chronic hepatitis B. Clin Infect Diseases Off Publ Infect Diseases Soc Am. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa013.","journal-title":"Clin Infect Diseases Off Publ Infect Diseases Soc Am"},{"key":"2211_CR36","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/jvh.13195","volume":"26","author":"U Limothai","year":"2019","unstructured":"Limothai U, Chuaypen N, Poovorawan K, et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e-antigen-negative chronic hepatitis B. J Viral Hepat. 2019;26:1481\u20138.","journal-title":"J Viral Hepat"},{"key":"2211_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3851\/IMP3280","volume":"24","author":"H Liao","year":"2019","unstructured":"Liao H, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside\/nucleotide analogue therapy. Antivir Ther. 2019;24:105\u201315.","journal-title":"Antivir Ther"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02211-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:12:25Z","timestamp":1742371945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02211-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2211"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02211-5","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no affiliations with or involvement in any organization with any financial or non-financial interests in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the participants provided written informed consent. This study was approved by the Ethics Committee of Hiroshima University, Hiroshima, Japan (Approved ID: E2016-0704). This study was conducted in accordance with the principles of the Declaration of Helsinki. All authors declare that they have no affiliations with or involvement in any organization with any financial or non-financial interests in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}